Merck price target raised to $143 from $140 at Berenberg

Berenberg raised the firm’s price target on Merck to $143 from $140 and keeps a Buy rating on the shares. The firm increased its Winrevair peak sales forecast to $6.8B from $4.8B following its “broad” U.S. approval in pulmonary arterial hypertension and higher than expected price. The label allows for convenient, at-home administration without onerous safety monitoring, the analyst tells investors in a research note. The firm believes Merck is well positioned to deliver above sector average sales growth and margin expansion in the medium term.